NNC 0128-0000-2011

NNC 0128-0000-2011 is a specific serum-free formulation of NNC 0128 (also known as N7-GP or eptacog alfa pegol), a long-acting, glycopegylated recombinant activated factor VII (rFVIIa) developed by Novo Nordisk. It was designed as a bypassing agent for the treatment and prophylaxis of bleeding in patients with hemophilia A or B who have developed inhibitors against factor VIII or IX. The glycopegylation technology extends the half-life of the rFVIIa molecule, potentially reducing the frequency of intravenous injections required for effective prophylaxis compared to conventional rFVIIa. NNC 0128 works by binding to tissue factor at the site of vascular injury, where it directly activates factor X and factor IX, bypassing the need for the intrinsic pathway factors VIII and IX to generate thrombin and initiate clot formation. Although it reached Phase 3 clinical development, Novo Nordisk discontinued the program in 2013.

Other names

eptacog alfa pegolglycopegylated recombinant activated factor VII